Mitchell Stern has over 25 years of investment banking experience, having closed over 40 transactions totaling more than $4 billion in aggregate value. Mr. Stern joined Dresner Partners in January 2012 as a Managing Director responsible for the Healthcare sector. Before joining Dresner Partners, Mr. Stern was a Managing Director in Healthcare Investment Banking at Morgan Joseph. He has also held positions with SMH Capital (Sanders Morris Harris), Glocap Advisors, Needham & Co., Schroders plc (Wertheim Schroder), and Salomon Brothers. In addition, Mr. Stern worked for the M&A Transactions Group at Deloitte & Touche and was a Certified Public Accountant (C.P.A.) with Ernst and Whinney (now Ernst & Young).
Mr. Stern has been involved in a variety of domestic and cross-border middle market valuation, capital raising and M&A transactions in the areas of healthcare services/healthcare IT, medical devices/products, and nutraceuticals/pharmaceuticals. Within healthcare services/HCIT, Mr. Stern has worked on some of the largest transactions in the long-term care sector, including the $1.4 billion acquisition of The Multicare Companies by Genesis Health Ventures, Texas Pacific Group and Cypress Group. He has also worked on the initial public offering for United Payors & United Providers (specialty managed care); the sale of Millennix (CRO) to IT&E International and The Comvest Group; and a follow-on offering for HBO & Co. (healthcare information systems) prior to its sale to McKesson. In medical products/life sciences, Mr. Stern has worked on financings for Innotech (ophthalmology devices) prior to its sale to J&J; ValveXchange (heart valves), Neurex (pain management) and Medgenics (protein therapeutics), as well as the merger of four publicly-traded companies into ICN Pharmaceuticals and the sale of Alan James Group (nutraceuticals) to Interleukin Genetics.
M.B.A. Finance, New York University
B.A. Accounting, Franklin and Marshall College